The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies
Jiayao Chen, Hongrui Yan, Haoyu Wang, Huixin Li, Zhiyu Wang, Qian Ding, Yi Zhun Zhu · 2026
Read The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies by Jiayao Chen, Hongrui Yan, Haoyu Wang, Huixin Li, Zhiyu Wang, Qian Ding, Yi Zhun Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13547457.txt.
Description
Jiayao Chen and others looked at liver cancer therapy design plans in 2026. Hepatocellular carcinoma causes many cancer deaths. Surgery and drugs help only partly. Return of the cancer and failed drugs limit lasting benefit. The tumour setting shapes drug acts. Prodrugs can switch on inside that setting.
Designs that sense their setting are the review focus. Metered tumour drug dose is the promise. Survival benefit cannot be assumed yet. Less harm also remains unproven in clinics. Marker-guided switching-on should come first. Multi-input designs may sharpen aiming. Making them must stay doable at scale. Real-world value remains to be shown. Smarter prodrugs remain a new field.
Catalog record
| CREATOR | Jiayao Chen, Hongrui Yan, Haoyu Wang, Huixin Li, Zhiyu Wang, Qian Ding, Yi Zhun Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 135 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |